GBG
Government
Bioscience
Grants

Updated Monthly

September 11, 2024

Prepared for:

BIOUTAH

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:

G2G Consulting

Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com
@G2Gconsulting

GBG Report

Updated Monthly

September 11, 2024

https://www.g2gconsulting.com/gbg-reporting-service/

TABLE OF CONTENTS

New Opportunities

Recurring Opportunities

September 19, 2024 – Join us for G2G's Monthly Non-Dilutive Funding: GBG Reporting Service Webinar at 12-12:30pm EDT (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you're an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Health Industry Forum, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

Women's Health Innovation Summit: The G2G Women's Health team will be in Boston from September 23-25. Founder Liz Powell will lead a discussion about **Advocacy in Women's Health: Strategies for Driving Change and Innovation** on the final day of the conference.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (3)		
1.	The Impact of Stressors on the Biological Mechanisms of Aging and Other Aging-Associated Outcomes in Experimental Model Systems (R61/R33 Clinical Trial Not allowed) (NIH/NIA) RFA-AG-25-019	This NOFO invites applications proposing research that incorporates exposures to a stressor(s) during the post-development period ("adulthood") into studies of aging processes. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-019.html	Up to $250,000 per year, for up to 3 years (R61) Up to $500,000 per year, for up to 3 years (R33)	Letter of intent: 10/7/24 Proposal: 11/7/24
2.	Understanding the mechanisms underlying the age-related changes in gait biomechanics and the impact on the increased metabolic cost of walking (R01 Clinical Trial Optional) (NIH/NIA) RFA-AG-25-030	This NOFO solicits applications that propose human studies to better understand the mechanisms underlying compensatory gait, posture, and molecular changes that contribute to slower walking speed and increased metabolic cost of walking. Areas of interest include: 1) mechanisms and effects of central nervous system changes; 2) neuromuscular changes; 3) skeletal muscle bioenergetics; 4) computational modeling and simulation; and 5) changes in tissue structure and function. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-030.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 10/7/24 Proposal: 11/7/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING		
3.	2025 NIA Start-Up Challenge and Accelerator (NIH/NIA)	This Challenge invites submissions from researchers and entrepreneurs who have innovative ideas for science-driven technologies and products that have the potential to increase the impact and reach of NIA-funded small business research and development, and who would substantially benefit from intensive entrepreneurial training and resources. https://www.challenge.gov/?challenge=2025-nia-start-up-challenge-and-accelerator	Up to $65,000	Proposal: 12/9/24
		AGRICULTURE (1)		
4.	Specialty Crop Research Initiative (USDA/NIFA) USDA-NIFA-SCRI-010974	The purpose of the SCRI program is to address the critical needs of the specialty crop industry by awarding grants to support research and extension that address key challenges of national, regional, and multi-state importance in sustaining all components of food and agriculture. Projects must address at least one of five focus areas. https://www.nifa.usda.gov/grants/funding-opportunities/specialty-crop-research-initiative	Up to $2 million	Proposal: 11/8/24
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (1)		
5.	Draft: Performance and Reliability Evaluation for Continuous modifications and uSEability of AI (PRECISE-AI) (ARPA-H) ARPA-H-SOL-25-113	PRECISE-AI aims to create a suite of self-correction techniques that make it possible to automatically maintain peak model performance of predictive AI components across diverse clinical settings. PRECISE-AI will advance novel approaches to optimally support clinician decision-making and scalably manage the performance of AI Decision Support Tools (AI-DSTs) after their commercial deployment. https://sam.gov/opp/e2daa542a6ea493d8ff7002836090702/view	Dependent upon proposal and award mechanism	TBD
		BIOMEDICAL RESEARCH (1)		
6.	Forecast: Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional) (NIH Common Fund) NOT-RM-24-012	Complement-ARIE is expected to significantly advance understanding of human health and disease by providing a range of mature and/or validated and standardized biomedical research models. Developing these models will require multi-disciplinary expertise in in vitro, in silico and in chemico approaches focused on modeling and understanding human diseases and conditions, personalized medicine, environmental science, and in screening therapeutics for safety and effectiveness and environmental compounds for health hazards. https://grants.nih.gov/grants/guide/notice-files/NOT-RM-24-012.html	Up to $2 million per year	Estimated post date: 10/18/24 Estimated proposal date: 2/28/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOTECHNOLOGY AND BIOMANUFACTURING (2)		
7.	On-Demand Manufacturing (BARDA/RRPV) RRPV 24-02-ODM	This program aims to identify, develop, and implement novel manufacturing technologies that will improve the speed, scale, and flexibility of MCM production and delivery at reduced cost while maintaining high levels of product integrity and quality. For this particular effort, targeted toward capabilities for on-demand manufacturing, it is important to note that development and optimization of the process, as opposed to generation of a particular product, is the primary interest. https://www.rrpv.org/solicitation/rpp-24-02-odm/	Total funds of $22 million	Abstract: 9/25/24
8.	Project Call 8.1 (NIIMBL)	Through Project Call 8.1, NIIMBL intends to fund innovative, collaborative, member-led projects that advance manufacturing technologies, builds awareness of biopharmaceutical manufacturing careers, and enhances manufacturing capabilities for mRNA vaccines. https://www.niimbl.org/projects-programs/project-call-8-1/	Up to $500,000, for up to 18 months Must be NIIMBL member Cost sharing required	Concept paper: 9/30/24 Proposal: 1/31/25
		CANCER (10)		
9.	POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in ONcology) (ARPA-H) ARPA-H-SOL-24-109	The POSEIDON program aims to fundamentally change the field of cancer screening by developing first-in-class, over-the-counter, MCED tests that screen for 30+ cancers at Stage 1. POSEIDON intends to develop non-invasive synthetic sensors and reporters to reliably detect cancer from breath or urine samples at home. The self-administered kit, based on human-centered design, would allow any adult American to screen for cancers before symptoms arise. The kit would also integrate results securely with electronic health records and ensure individuals connect with a health care professional via a telemedicine call to review results. https://sam.gov/opp/1e9af44bfff44a36be4b730a5707c183/view	Dependent upon proposal and award mechanism	Solution Summary: 11/6/24 Proposal: 1/8/25
10.	Basic Research in Cancer Health Disparities (R01/R21 Clinical Trial Not Allowed) (NIH/NCI) PAR-24-277 (R01) PAR-24-291 (R21)	These NOFOs encourage applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These grants will support studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. https://grants.nih.gov/grants/guide/pa-files/PAR-24-277.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-291.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Proposal: 10/5/24 (R01) Proposal: 10/16/24 (R21)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
11.	Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01/R21 Clinical Trial Optional/Not Allowed) (NIH/NCI) PAR-25-043 (R01) PAR-25-044 (R21)	The goal of these NOFOs is to support investigator-initiated studies addressing mechanisms by which bariatric surgery impacts cancer risk and seeks to draw in talented scientists who study bariatric surgery to investigate its effects on cancer, rather than shorter term outcomes such as weight loss and diabetes, as well as proof of concept studies for feasibility and exploratory development. https://grants.nih.gov/grants/guide/pa-files/PAR-25-043.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-25-044.html (R21)	Up to $500,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 1/7/28
12.	Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required) (NIH/NCI) RFA-CA-24-025	The purpose of CP-CTNet is to perform early phase clinical trials to evaluate the biologic effects of preventive agents and interventions and to determine clinically-relevant correlates in order to advance their development for cancer prevention. The DMASC is expected to provide multi-disciplinary expertise in information technology, clinical research informatics, clinical trials auditing, clinical trials methodology and biostatistics, and operations management to support CP-CTNet activities. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-025.html	Up to $2 million per year, for up to 6 years	Letter of intent: 9/30/24 Proposal: 10/31/24
13.	NCI Genomic Data Commons (GDC) Analysis Tool Challenge (NIH/NCI)	Challenge objectives are: 1) Provide the research community with a novel analysis tool to analyze data in the GDC in support of cancer research, 2) Use the GDC Analysis Tool Software Development Kit (SDK) to integrate an Analysis Tool with the GDC using data available in the GDC in support of cancer research. The winning analysis tools will be made available in the GDC Data Portal Analysis Center to reach a broader audience of cancer researchers. https://www.challenge.gov/?challenge=nci-gdc-analysis-tool-challenge	Total prizes of $50,000	Proposal: 10/31/24
14.	Forecast: FY24 Glioblastoma Research Program (DoD/CDMRP)	Two awards are anticipated: Hypothesis Development Award and Resource Development Award. Applications must address one or more of the Focus Areas. The HDA Focus Areas are Biomarkers and Drug Delivery; the RDA Focus Area is Models. https://cdmrp.health.mil/pubs/press/2024/24gbmrppreann	Up to $500,000, for up to 3 years Dependent upon award mechanism	TBD
15.	Biomedical Quantum Computation Challenge (NIH)	NCI is seeking Participants with ideas for data science problems in a cancer-relevant field of research for which novel quantum algorithms can be developed that demonstrate a clear quantum advantage over classical computation approaches, using real world cancer research data. https://www.challenge.gov/?challenge=bqcc	Total prizes of $100,000	Proposal: 10/13/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH (2)		
16.	NOSI: Stimulate Research on the Diagnosis, Treatment, and Mechanistic Understanding of Postural Orthostatic Tachycardia Syndrome (POTS) (NIH) NOT-HL-24-018	There is a compelling need to stimulate research focused on improving diagnosis and treatment of POTS. This may include development of biomarkers and diagnostic tools as well as translational studies and mechanistic clinical trials to guide the development of interventions aimed at preventing and curing POTS. This NOSI signals interest in this important area with the goal of stimulating research applications to address these critical needs. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-24-018.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/28
17.	Forecast: Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional) (NIH/NHLBI) NOT-HL-24-027	This NOFO will support a consortium to phenotype 0-2 year old children with severe viral lower respiratory tract infections (LRTI) with follow up until pre-school age for pulmonary sequelae. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-24-027.html	TBD	Estimated post date: 1/13/25 Estimated proposal date: 6/13/25
		CENTRAL NERVOUS SYSTEM (1)		
18.	Blueprint Medtech Incubator Hub Cycle 5 (NIH)	Innovators developing groundbreaking medical device technologies face several challenges along the translational path from bench to bedside. The NIH Blueprint MedTech: Incubator Hubs aim to address such challenges by accelerating the development of cutting-edge medical devices that will prevent, diagnose, and/or treat disorders involving the nervous system or consequences of such a disease or injury. https://blueprintneurotech.org/	Up to $500,000 per year, for up to 4 years Dependent upon award mechanism	Pre-proposal: 10/4/24 Invited proposals: 11/27/24
		CHRONIC PAIN & PAIN MANAGEMENT (4)		
19.	Forecast: Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01) Clinical Trials Allowed (HHS/FDA) FOR-FD-25-009	Research is needed in the following fields: function as a clinical trial endpoint and measurement of function in patients with chronic pain, outcome measures for clinical trials in stimulant use disorders, assessment of opioid clinical trials with active control in addition to placebo, neurodevelopmental outcome assessment of vulnerable pediatric patients exposed to anesthesia and opioid, and a living systematic review of pre-clinical studies of anesthetic neurotoxicity. Applicants must propose a comprehensive evidence-based plan that advances appropriate prescribing of drug products intended for analgesia, anesthesia, and substance use disorders. https://www.grants.gov/search-results-detail/356049	Up to $2 million	TBD

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CHRONIC PAIN & PAIN MANAGEMENT		
20.	NOSI: HEAL Initiative: Development and Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech (NIH) NOT-NS-24-075	This NOSI encourages the development and translation of novel neurotechnologies, and solicits grant applications that propose non-clinical development and validation activities for subsequent clinical feasibility studies of medical devices for the diagnosis and treatment of pain and OUD. Applications supporting the development and translation of groundbreaking neurotechnologies that fit within the mission of the HEAL Initiative are encouraged. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-075.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 2/28/28
21.	HEAL Initiative: NIH-DOD-VA Pain Management Collaboratory – Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required) (NIH/DoD/VA) RFA-AT-24-011	The purpose of this NOFO is to solicit research applications to conduct efficient, large-scale pragmatic clinical trials and/or implementation science demonstration projects within the infrastructure of the NIH-DOD-VA Pain Management Collaboratory (PMC) on nonopioid approaches to management of pain and other comorbid conditions, including complementary and integrative approaches used alone and in combination with standard care (e.g., mindfulness meditation combined with standard pharmaceutical treatment), and improving prevention and treatment for opioid misuse and addiction in U.S. Veterans, military personnel, and their families. https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-24-011.html	Up to $500,000 per year, for up to 1 year (UG3) Up to $1 million per year, for up to 4 years (UH3)	Letter of intent: 10/7/24 Proposal: 11/7/24
22.	Forecast: Managing Pain Topical PCORI Funding Announcement -- Cycle 1 2025 (PCORI)	PCORI seeks to fund studies that address meaningful decisional dilemmas faced by patients, clinicians and members of the broader health and healthcare community when seeking and obtaining pain-related care and to improve patient-centered outcomes. PCORI is particularly interested in submissions that address the following Special Areas of Emphasis (SAEs): Urogynecological and pelvic pain; Pain in individuals living with limitations in cognitive functioning; Pain in individuals living with sickle cell disease; and Neuropathic pain. https://www.pcori.org/funding-opportunities/announcement/managing-pain-topical-pcori-funding-announcement-cycle-1-2025	Up to $12 million, for up to 5 years	System opens: 12/3/24 Letter of intent: 1/14/25 Proposal: 5/6/25
		COGNITIVE AND BRAIN HEALTH (5)		
23.	Forecast: BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional) (NIH) NOT-MH-24-365	This NOFO will solicit applications for research on the development and preclinical testing of novel sensors and bioelectronics that will improve our understanding of human and animal behavior as part of the Brain Behavior Quantification and Synchronization Program. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-365.html	TBD	Estimated post date: 10/14/24 Estimated proposal date: 6/13/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
24.	Forecast: BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed) (NIH/NINDS) NOT-NS-24-130	This NOFO will solicit projects developing scalable methods for mapping brain connectivity, applied to any aspect of the pipeline, from tissue processing to imaging, alignment, segmentation and annotation, error correction, and integration into the larger neuroscience data environment. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-130.html	TBD	Estimated post date: 9/13/24 Estimated proposal date: 6/2/25
25.	ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed) (NIH/NINDS/NIA) PAR-24-270	This NOFO will support research projects that take this research further by determining how exogenous ERFs affect ADRD disease mechanisms and phenotypic outcomes through innervated human surfaces. Exogenous ERFs include toxins and toxic chemicals, other pathogens, and other environmental exposures that reach innervated human surfaces. https://grants.nih.gov/grants/guide/pa-files/PAR-24-270.html	Up to $500,000 per year, for up to 5 years	Proposal: 11/19/24
26.	Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-25-026	This NOFO invites applications that investigate mitochondrial-nuclear communication in the context of neurobiology and AD/ADRD. This research will transform our understanding of how mitochondrially derived metabolites can impact nuclear gene expression and how changes to nuclear function can impact mitochondrial activity. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-026.html	Dependent upon proposal, for up to 5 years	Letter of intent: 10/7/24 Proposal: 11/7/24
27.	Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) (NIH/NINDS/NIA) RFA-NS-24-037	This NOFO supports the optimization of promising genome editing-based therapeutic leads for ADRD, by advancing therapeutic candidates towards ND-enabling studies. It supports the development of therapeutic lead(s) that show potential as genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-037.html	Up to $1 million per year, for up to 5 years	Proposal: 11/19/24
		COMBAT CASUALTY CARE (1)		
28.	SBIR: Direct Blood Oxygenation Titration System (D-BOTS) (DoD/DARPA) HR0011SB20244-04	DARPA is interested in novel approaches to develop a breadboard system that can integrate with prototype intravascular oxygenation catheters to automatically deliver O_2 directly to a patient's bloodstream following catheter insertion. https://www.dodsbirsttr.mil/topics-app/	Up to $1.2 million, for up to 1 year	Proposal: 10/22/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COMPLEMENTARY AND INTEGRATIVE HEALTH (1)		
29.	NOSI: Fundamental Science Research on Complementary and Integrative Health Approaches, Including Natural Products or Mind and Body Interventions (NIH/NCCIH) NOT-AT-24-041	Basic and mechanistic research on complementary and integrative health approaches should investigate the following key aspects. The first is the approach (also called intervention) itself, the second is the biological, behavioral, psychological, and/or social systems potentially targeted by the approach or intervention, and the third is the platform in which they will be studied. https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-041.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 10/17/27
		DENTAL AND CRANIOFACIAL RESEARCH (8)		
30.	NOSI: Advancing Precision Imaging for Enhanced Diagnosis and Treatment of Oral Lesions (NIH/NIDCR) NOT-DE-25-034	By integrating cutting-edge imaging modalities into clinical workflows, optimizing lesion detection methods, and refining single-cell analysis, this NOSI seeks to bridge existing gaps in precision imaging for oral diseases. The long-term goal is to establish standardized quantitative imaging metrics, integrate imaging into clinical trials, and combine imaging data with multi-omics information for comprehensive profiling of oral lesions. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-25-034.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/7/27
31.	Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R01/R21 Clinical Trial Not Allowed) (NIH/NIDCR/OD) RFA-DE-25-001 (R01) RFA-DE-25-002 (R21)	These NOFOs encourage interdisciplinary research that advances the validation of organ-on-a-chip (OoC) towards disease modeling and pre-clinical efficacy studies in dental, oral, and craniofacial (DOC) research. https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-25-001.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-25-002.html (R21)	Up to $500,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Letter of intent: 10/19/24 Proposal: 11/19/24
32.	Collaborative Science to Achieve Disruptive Innovations in Dental, Oral and Craniofacial (DOC) Research (RM1 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DE-25-004	This NOFO is designed to support highly integrated research teams to address challenging questions with the potential to significantly advance dental, oral and craniofacial (DOC) fields of research. Each project should have a unified and well-defined scientific goal within the NIDCR mission that requires a team with diverse perspectives and expertise in a variety of intellectual or technical areas and is beyond the experience and capabilities of one or two investigators. https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-25-004.html	Up to $750,000 per year, for up to 5 years	Letter of intent: 10/20/24 Proposal: 11/19/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE (2)		
33.	Polycystic Kidney Disease Core Centers and Central Coordinating Site (U24/U54 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-25-015 (U24) RFA-DK-25-016 (U54)	The Central Coordinating Site is expected to work collaboratively with the PKD Core Centers as part of the PKD RRC and serve as a national resource for the larger research community. The PKD Core Centers are designed to support and enhance the national research effort in PKD through developing and broadly sharing innovative research tools and resources. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-015.html (U24) https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-016.html (U54)	Up to $600,000 per year, for up to 5 years	Letter of intent: 10/14/24 Proposal: 11/14/24
		GENOMICS (10)		
34.	NOSI: Small Business Solutions to Assist Genomics-Enabled Learning Health Systems (gLHS) (NIH/NHGRI) NOT-HG-24-040	A variety of solutions that can assist gLHS are needed. NHGRI will consider applications that address barriers, which include but are not limited to, setting up gLHS; conducting outreach, promotion, and education about gLHS; and/or running gLHS. Eligible small businesses can submit applications focusing on solutions that reduce costs, time, and/or increase access to gLHS. https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-040.html	Up to $306,872, for up to 1 year (Phase I) Up to $2,045,816, for up to 2 years (Phase II) Certain topics may exceed these amounts	Multiple deadlines; NOSI open through 9/5/27
35.	NOSI: Small Business Solutions to Enable Regional Genomic Medicine eConsult Services (NIH/NHGRI) NOT-HG-24-041	A variety of solutions that can enable eConsult services are needed. NHGRI will consider applications that address barriers to setting up eConsult services; conducting outreach, promotion, and education about eConsult services; and/or providing eConsults. https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-041.html	Up to $306,872, for up to 1 year (Phase I) Up to $2,045,816, for up to 2 years (Phase II) Certain topics may exceed these amounts	Multiple deadlines; NOSI open through 9/5/27
36.	STTR Solutions to Enable Population Genomic Screening (R41/R42 Clinical Trial Optional) (NIH/NHGRI) PAR-24-262 (R41/R42) PAR-24-263 (R43/R44)	These NOFOs solicit applications to develop innovative solutions for commercialization that would enable population genomic screening for common, actionable genomic conditions predominantly in the primary care setting. https://grants.nih.gov/grants/guide/pa-files/PAR-24-262.html (R41/R42) https://grants.nih.gov/grants/guide/pa-files/PAR-24-263.html (R43/R44)	Up to $400,000, for up to 1 year (Phase I) Up to $2.15 million, for up to 2 years (Phase II)	Letter of intent: 11/2/24 Proposal: 12/2/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA (2)		
37.	Forecast: Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed) (NIH/NLM) NOT-LM-24-003	NLM wishes to accelerate access to, and availability of, secure, complete datasets and computational models that can serve as the basis for transformative biomedical discoveries. Innovative at-scale computational approaches that increase the speed and scope of curation processes are needed for data mining and knowledge discovery from growing quantities of biomedical data produced from ongoing data science advances. https://grants.nih.gov/grants/guide/notice-files/NOT-LM-24-003.html	Up to $250,000 per year	Estimated post date: 10/15/24 Estimated proposal date: 2/5/25
38.	2024 DataWorks! Prize (NIH)	The DataWorks! Prize recognizes the impactful role of data reuse on human health. Successful submissions must: Address a pivotal health research question via data reuse and secondary data analysis; Include data from at least one GREI organizations; Share results with the broader community. https://www.challenge.gov/?challenge=2024-dataworks-prize	Up to $100,000	Proposal: 10/23/24
		HIV/AIDS (10)		
39.	Strategies for Eliminating HIV Proteins (R01/R21 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-24-057 (R01) RFA-AI-24-064 (R21)	These NOFOs support the development of molecules that target HIV proteins or RNA for degradation or that interfere with the translation of HIV RNA into protein. This approach has the potential of eliminating HIV proteins that have been difficult to target via traditional drug discovery methodologies. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-057.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-064.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Letter of intent: 11/4/24 Proposal: 12/4/24
40.	Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-25-063	This NOFO seeks applications that examine protein interaction networks in HIV-infected microglia, and how these host-viral interactions contribute to cell type- and brain region-specific alterations in cellular signaling in the context of comorbid HIV and substance use disorder (SUD). https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-063.html	Dependent upon proposal, for up to 5 years	Letter of intent: 7/14/25 Proposal: 8/14/25
41.	Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-25-073	This NOFO will support high-risk, high-impact studies that 1) develop or apply novel tools or technologies or 2) test novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-073.html	Up to $700,000 per year, for up to 5 years	Letter of intent: 7/14/25 Proposal: 8/14/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
42.	Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01/R21 Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-26-001 (R01) RFA-DA-26-002 (R21)	These NOFOs support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/ART and SUD-relevant molecular responses, and/or to support functional validation studies to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-001.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-002.html (R21)	Up to $350,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Multiple deadlines; NOFOs open through 3/19/26
43.	Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01/R21 Clinical Trials Not Allowed) (NIH/NIDA) RFA-DA-26-007 (R01) RFA-DA-26-008 (R21)	These NOFOs support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this knowledge to explore biological mechanisms as potential therapeutic targets to address HIV-substance use disorder (SUD) comorbidity. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-007.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-008.html (R21)	Up to $400,000 per year, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Letter of intent: 2/12/25 Proposal: 3/13/25
44.	Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional) (NIH/NIDDK) RFA-DK-25-024	This NOFO seeks to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the NIDDK. These teams will comprehensively interrogate fundamental biological mechanisms underlying HIV-associated comorbidities, co-infections, and complications relevant to the mission of NIDDK and advance progress toward preventing or alleviating them. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-024.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 10/21/24 Proposal: 11/21/24
45.	Pediatric HIV/AIDS Cohort Study (PHACS) (U19 Clinical Trial Not Allowed) (NIH) RFA-HD-25-003	The purpose of this NOFO is to support the Pediatric HIV/AIDS Cohort Study (PHACS) as a transformative and agile program addressing the developmental and clinical course of persons living with HIV, and perinatally acquired HIV, with an emphasis on youth through reproductive age in the United States. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-25-003.html	Up to $5.5 million per year, for up to 5 years	Letter of intent: 11/5/24 Proposal: 12/11/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE (3)		
46.	Deployed Warfighter Protection (DWFP) Program for the Protection of Deployed Military Personnel from Threats Posed by Arthropod Disease Vectors (DoD/Army) AFPMB-BAA-25-01	Applications must address at least one of these FY25 DWFP Program Research Areas: bite prevention, vector control, decision support tools or software applications, vector surveillance and identification, and/or vector pathogen diagnostics. https://www.grants.gov/search-results-detail/356270	Up to $975,000	Proposal: 1/28/25
47.	NextGen Oral Formulation Vaccines for COVID-19 (BARDA/RRPV) RRPV 24-02-OralVx	BARDA is requesting project proposals from developers to advance next generation oral vaccine formulations and technologies for COVID-19 into proof-of-concept Phase 1 trials. Oral delivery of vaccines offers several potential benefits for pandemic preparedness over traditional needle/syringe-based delivery, including: ease of administration from the perspective of both those administering vaccines and people receiving vaccines; generation of mucosal immunity at the site of infection; potential for reduced cold chain reliance; and improved distribution and administration logistics. https://www.rrpv.org/solicitation/nextgen-oral-formulation-vaccines-for-covid-19/	Up to $5 million, for up to 2 years (Stage 1) Up to $8 million, for up to 2 years (Stage 2)	Proposal: 10/18/24
48.	Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability (BARDA/RRPV) RRPV-24-08-mRNALongTerm	BARDA envisions an initial focus on influenza mRNA vaccine development that complements existing pandemic influenza response capabilities. As the program matures beyond licensure of influenza vaccines, there will be increased focus on continually 'exercising' preparedness and response efforts at small scale to ensure readiness to rapidly pivot to address pandemic influenza or any other emerging infectious disease that poses a threat. The penultimate goal for this program is to serve as a critical component of the Nation's pandemic response for influenza and any other emerging infectious diseases, collaboratively working with BARDA to develop multiple products using a single, flexible platform capability. https://www.rrpv.org/solicitation/rpp-24-08-mrnalongterm/	Dependent upon proposal and award mechanism, for up to 10 years	Proposal: 12/16/24
		MENTAL HEALTH (12)		
49.	NOSI: Developing and Delivering Feasible Screening Methods and Tools for Eating Disorders (NIH/NIMH) NOT-MH-24-380	This NOSI, with 12 linked grants, encourages applications that investigate the development and delivery of screening methods for subthreshold and diagnosable eating disorders in naturalistic settings for children, adolescents, and adults. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-380.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/7/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MICROGRAVITY RESEARCH (3)		
50.	Igniting Innovation: Science in Space to Cure Disease on Earth (NASA) NLRA 2024-9	This NLRA seeks proposals for flight projects that utilize the unique space environment to address challenges that hinder progress in preventing, diagnosing, and treating some of the most challenging diseases of our time, such as cancer. Similarly, advanced therapies for cardiovascular, immune, muscle and bone, and neurodegenerative diseases face obstacles that thwart scientific advancements and the translation of research findings into clinical applications. These challenges frequently overlap and share common elements, despite the complexity and variability of mechanisms within and among these diseases. Many of these challenges can be mitigated using accelerated disease models in microgravity. https://www.issnationallab.org/research-on-the-iss/solicitations/nlra2024-9/	N/A	Concept Summary: 9/26/24
		MUSCULOSKELETAL HEALTH (3)		
51.	FY24 Arthritis Research Program (ATRP) (DoD/CDMRP) HT942524ATRPCRA (CRA) HT942524ATRPFRA (FRA)	Applications submitted to the FY24 ATRP must address one or more of the following focus areas, not all of which will be applicable to every award mechanism: Prevention; Diagnosis and Progression Mitigation; and Intervention/Treatment. Two awards are posted: Clinical Research Award and Focused Research Award. https://cdmrp.health.mil/funding/atrp	Up to $3 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 10/16/24 Proposal: 10/30/24
52.	NOSI: Supporting Research Using the Resources from the Osteoarthritis Initiative (OAI) (NIH/NIAMS/NIA) NOT-AR-24-019	This NOSI solicits grant applications that are focused on the use of the OAI database, clinical data, and images. While the Osteoarthritis Initiative resource has been used widely by OAI investigators, musculoskeletal imagers, and others, rich opportunities remain for the exploration of OAI data and images, analysis of the epidemiology and natural history of osteoarthritis, and application of emerging technologies to the biospecimens and genetic data. https://grants.nih.gov/grants/guide/notice-files/NOT-AR-24-019.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/7/27
		PATIENT-CENTERED RESEARCH (7)		
53.	Promoting Healthy Children and Youth Topical PCORI Funding Announcement -- Cycle 3 2024 (PCORI)	This PFA will fund patient-centered comparative clinical effectiveness research (CER) projects that focus on interventions that improve patient-centered outcomes in children and youth. SAEs include: Prevention and treatment of obesity, Addressing social determinants of health/social needs to improve health outcomes, and Targeted prevention of substance misuse through identified risk factors. https://www.pcori.org/funding-opportunities/announcement/promoting-healthy-children-and-youth-topical-pcori-funding-announcement-cycle-3-2024	Up to $12 million, for up to 5 years	Letter of intent: 10/1/24 Proposal: 1/14/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
54.	Phased Large Awards for Comparative Effectiveness Research (PLACER) -- Cycle 3 2024 (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. Applications must address at least one of the National Priorities for Health. https://www.pcori.org/about/about-pcori/pcori-strategic-plan/pcori-strategic-plan-national-priorities-health https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-placer-cycle-3-2024	Up to $22 million, for up to 6.5 years	Letter of intent: 10/1/24 Proposal: 1/14/25
55.	Broad Pragmatic Studies Funding Announcement -- 2024 Standing PFA (Cycle 3 2024) (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of twelve topic themes, based on how their proposed research aligns with the themes. Cycle 3 SAEs include: Social Isolation and Loneliness in Older Adults, Health Communication Strategies for Uptake of COVID-19 Vaccine, and Promoting Sleep Health in Inpatient Settings. https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2024-standing-pfa-cycle-3-2024	Up to $12 million, for up to 5 years Dependent upon award mechanism	Letter of intent: 10/1/24 Proposal: 1/14/25
56.	Advancing the Science of Engagement PCORI Funding Announcement -- Cycle 3 2024 (PCORI)	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-3-2024	Up to $1.5 million, for up to 3 years	Letter of intent: 10/1/24 Proposal: 1/14/25
57.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research -- 2024 Standing PFA (Cycle 3 2024) (PCORI)	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-2024-standing-pfa-cycle-3-2024	Up to $750,000, for up to 3 years	Letter of intent: 10/1/24 Proposal: 1/14/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
58.	Implementation of Effective Shared Decision Making Approaches in Practice Settings -- Cycle 3 2024 (PCORI)	This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision making strategies that address existing barriers and obstacles to uptake and maintenance, so that these interventions are effectively and sustainably integrated into practice. The SDM strategy must have demonstrated effectiveness on patient, caregiver, or healthcare provider decision making using widely accepted metrics; the corresponding implementation approach must have potential for use and scalability beyond the targeted implementation setting. https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-pcori-funding-announcement-cycle-3-2024	Up to $2.5 million, for up to 4 years	Letter of intent: 10/1/24 Proposal: 1/14/25
59.	Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments -- Cycle 3 2024 (PCORI)	For this PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). https://www.pcori.org/funding-opportunities/announcement/open-competition-pcori-funding-announcement-implementation-findings-pcoris-research-investments-cycle-3-2024	Up to $2.5 million, for up to 3 years	Letter of intent: 10/1/24 Proposal: 1/14/25
		RARE DISEASES (2)		
60.	Draft: Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ARPA-H) ARPA-H-MAI-24-01-07	The DECIDE ET endeavors to produce tools and technology that enable accelerated evaluation and validation of GMP for small batch therapies by demonstrating product quality and consistency that is commensurate with the amount of therapy that needs to be produced. DECIDE seeks to ensure access to critical therapeutic solutions for Americans and provide a revolutionary pathway to address market failures by innovating approaches to right-size cell therapy production for pediatric rare disease. https://sam.gov/opp/44a7073a51894651a2e38487ba82f49c/view	Dependent upon proposal and award mechanism	Proposal: 10/22/24
61.	Forecast: Studies Addressing Rare Neurodegenerative Diseases including ALS (FDA) FOR-FD-25-006	This FOA will support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development. https://www.grants.gov/search-results-detail/356046	TBD	TBD

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		RECONSTRUCTIVE TRANSPLANT (1)		
62.	FY24 Reconstructive Transplant Research Program (RTRP) (DoD/CDMRP) HT942524RTRPQRVIA	The Qualitative Research Validation and Implementation Award has been posted. All applications must address at least one of the Focus Areas and sub-bullets. https://cdmrp.health.mil/funding/rtrp	Up to $500,000, for up to 3 years	Pre-Application: 10/9/24 Proposal: 10/23/24
		RESEARCH SUPPORT (1)		
63.	Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed) (NIH) PAR-24-258	The overall goal of the research resource is to provide a wide variety of human tissues and organs, both diseased and normal, to investigators. The research resource is expected to facilitate the procurement and preservation of human tissues and organs as well as the distribution of these materials to qualified biomedical researchers. https://grants.nih.gov/grants/guide/pa-files/PAR-24-258.html	Up to $720,000, for up to 5 years	Multiple deadlines; NOFO open through 9/26/25
		SUBSTANCE USE DISORDER (8)		
64.	NOSI: Model-informed Drug Development (MIDD) Approaches to Facilitate the Development of Therapeutics for Substance Use Disorders (NIH/NIDA) NOT-DA-26-002	This NOSI encourages research applications that use MIDD approaches to: Predict drug toxicology profile, pharmacokinetics, ADME, biopharmaceutical properties, and drug-drug interactions; Assist in pre-formulation studies, formulation design and optimization; Optimize clinical trial design through modeling and simulation to increase the success rate; Develop precision medicines or personalized treatment plans for special patient sub-populations; and Support efficacy extrapolation in a new patient population, the use of different routes of administration, a new dosage form, and a new dose regimen. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-26-002.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/7/28
65.	NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed) (NIH/NIDA) PAR-24-269	The purpose of this program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie neural and behavioral processes and phenotypes relevant to SUD risk, the SUD trajectory and SUD comorbidities. This opportunity supports research that links genetic, genomic and molecular mechanisms to neural circuit function and behavior. Applications may seek to identify any type of genomic and/or epigenomic variants that contribute to the genetic architecture of addiction. https://grants.nih.gov/grants/guide/pa-files/PAR-24-269.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 2/11/27
		THERAPEUTICS (1)		
66.	Forecast: Center for Research on Complex Generics (U18) Clinical Trials Optional (FDA) FOR-FD-25-004	The Center for Research on Complex Generics is expected to complement FDA's existing regulatory science programs through its specific focus as a hub for coordination and engagement between FDA and the public, including academic experts, generic industry representatives, and other stakeholders. https://www.grants.gov/search-results-detail/356044	Up to $1.5 million	TBD

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS		
67.	Forecast: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3/U44 Clinical Trial Optional) (NIH) NOT-NS-24-014 (UG3/UH3) NOT-NS-24-015 (U44)	BPN Biologics aims to accelerate the development of diverse biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene and cell therapies, and other emerging modalities, for the treatment of nervous system and neuromuscular disorders. BPN Biologics provides funding, resources, and expertise for drug discovery and development activities, from lead optimization through first-in-human clinical trials. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-014.html (UG3/UH3) https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-015.html (U44)	TBD	Estimated post date: 10/1/24 Estimated proposal date: 1/27/25
68.	Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required (FDA/OOPD) RFA-FD-25-001	This NOFO will fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-001.html	Up to $900,000 per year, for up to 4 years	Multiple deadlines; NOFO open through 10/24/25
		WOMEN'S HEALTH (1)		
69.	RADx® Tech ACT ENDO Challenge (NIH/NICHD)	The RADx® Tech ACT ENDO Challenge seeks to accelerate the development of innovative technologies for the diagnosis of endometriosis. Novel approaches are urgently needed to identify those who are afflicted with the condition and to spur the development of new treatments and cures. Successful technologies will shorten the time to diagnosis, eliminate the invasiveness of current techniques, and/or improve accessibility, safety, convenience, and costs of diagnosis. https://www.challenge.gov/?challenge=radx-tech-act-endo	Total prizes of $3 million	Proposal: 10/11/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
70.	Office-Wide Innovative Solutions Opening for Resilient Systems Office (RSO) ARPA-H-SOL-24-103	RSO seeks solution summaries and proposals that drive innovations to enhance the adaptability, reliability, and interoperability of the health ecosystem. The following interest areas categorize the ground-breaking research we seek to support: Sociotechnical System Innovation; Health Ecosystem Integration; and Adaptive & Antifragile Solutions. https://sam.gov/opp/76679cd8810f40229694c60c0a593302/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
71.	Office-Wide Innovative Solutions Opening for Health Science Futures (HSF) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/opp/9a301dc812ba47268323e3130e381f19/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
72.	Office-Wide Innovative Solutions Opening for Scalable Solutions Office (SSO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, as well as flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Scalable Technologies and Interventions; Collaborative Distribution Networks; and Biomanufacturing Innovations. https://sam.gov/opp/134cdc5d93b34c0ea39498055f315624/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25
73.	Office-Wide Innovative Solutions Opening for Proactive Health Office (PHO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/opp/53707a1538994e7d9ed8df8e5ee95ed1/view	Dependent upon proposal and award mechanism	Solution Summaries: 3/3/25 Proposal: 3/15/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (3)		
74.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/search-results-detail/327332	Up to $49 million, per award	White papers accepted on rolling basis until 5/1/25
75.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/search-results-detail/345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
76.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
77.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
78.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
79.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
80.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; PFC; human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
81.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
82.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
83.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
84.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/search-results-detail/327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		BARDA (2)		
85.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/764c53aa6dac43538ef902a2bc2af44f/view	Dependent upon proposal	Proposal: 9/25/28
86.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for two AOIs: AOI #17: Digital MCMs and AOI #26: Agnostic Diagnostic. https://sam.gov/opp/5d6a4e1582c444b196dbef185231f74e/view	Up to $750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
87.	Biological Technologies BAA HR001123S0045	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/19/24
88.	Defense Sciences Office, Office-wide HR001123S0053	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. https://sam.gov/opp/972be70efd7e4608b01311466edf6b0f/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
89.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/3b8216acdcc44c46ada2511459918de5/view	Up to $1 million per year, for up to 5 years	White papers accepted through 9/2024
90.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E: • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
91.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
92.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8e0d71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
		DEPARTMENT OF ENERGY (1)		
93.	FY 2024 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003177	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/search-results-detail/350408	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NAVY (3)		
94.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001424SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/24
95.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/1e5fbd8c66d949fdb4cfe0afc8b0b76b/view	Dependent upon proposal and award mechanism	White papers accepted through 12/31/24
96.	FY24 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943024S2000	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/2397c9059c3942cfb618400b2d8637e2/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/7/25
		NATIONAL SCIENCE FOUNDATION (2)		
97.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 24-579	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View the full list of topics. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-0/nsf24-579/solicitation	Up to $275,000 for up to 1 year	Project pitches accepted on a rolling basis through 3/5/25.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION		
98.	NSF Small Business Innovation Research / Small Business Technology Transfer Fast-Track Pilot Programs (SBIR-STTR Fast-Track) NSF 24-582	The NSF SBIR/STTR Fast-Track programs provide non-dilutive, fixed amount cooperative agreements for the development of a broad range of technologies based on discoveries in science and engineering with the potential for societal and economic impacts. https://new.nsf.gov/funding/opportunities/nsf-small-business-innovation-research-small-1/nsf24-582/solicitation	Up to $1,555,000, for up to 3 years	Project pitches accepted on a rolling basis through 3/5/25. Proposal: 9/18/24

GBG Acronyms

Updated Monthly
September 11, 2024
https://www.g2gconsulting.com/gbg-reporting-service/

Terms
AD/ADRD: Alzheimer's Disease / Alzheimer's Disease Related Dementias
AoI: Area of Interest
BAA: Broad Agency Announcement
BBB: Blood-Brain Barrier
CNS: Central Nervous System
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
PTSD: Post-Traumatic Stress Disorder
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
SUD: Substance Use Disorder
TRL: Technology Readiness Level
VCID: Vascular Contributions to Cognitive Impairment and Dementia

Agencies
ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

NIH Institutes and Centers
CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Back to Table of Contents